BioCentury | Mar 15, 2021
Finance
Cell and gene therapy accelerator ElevateBio continues to refine ‘sweet spot’ with $525M series C
...as CSO of regenerative medicine. Carpenter previously led the development of stem cell programs at CytoTherapeutics...